JUNSHI BIO (01877.HK) Stock Community - Hot Topic Discussions

Quote List Quote List

Event Tracking

Dec18

Jushi Biopharma Shareholder Shanghai Tan Ying Plans to Reduce Holdings by No More Than 2%

10:54

Dec14

Junshi Biosciences' EGFR/HER3 Bispecific Antibody-Drug Conjugate JS212 Clinical Trial Approved by FDA

07:49

Dec10

Junshi Biosciences Chairman Xiong Jun Plans to Increase Shareholding

09:18

Dec7

Jusbio's New Drug Application for JS005 Receives Acceptance

11:20

Junshi Biopharma's Two Products Included in National Health Insurance Directory

07:35

Dec6

Junshi Biosciences Announces New Survival Rates for Toripalimab in Nasopharyngeal and Esophageal Squamous Cell Cancer at ESMO Asia Conference

03:11

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 696.89 M, Net Income -200.05 M, EPS -0.1974

Aug26

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 730.91 M, Net Income -194.63 M, EPS -0.1972

Apr25

Earning Release(CST)

FY2025 Q1 Earning Release (HKD) Revenue 536.12 M, Net Income -251.55 M, EPS -0.257

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change